Report cover image

Global Human-mouse Chimeric Antibody Market Growth (Status and Outlook) 2025-2031

Published Aug 06, 2025
Length 139 Pages
SKU # LPI20281020

Description

According to this study, the global Human-mouse Chimeric Antibody market size will reach US$ 27998 million by 2031.

A human-mouse chimeric antibody is a type of monoclonal antibody engineered by combining the variable regions of a mouse antibody (which determines antigen specificity) with the constant regions of a human antibody. This design reduces immunogenicity in humans compared to fully murine antibodies, while retaining the mouse antibody’s ability to bind its target. Chimeric antibodies are typically around 65–70% human and are used in the treatment of cancers, autoimmune diseases, and transplant rejection.

United States market for Human-mouse Chimeric Antibody is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

China market for Human-mouse Chimeric Antibody is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Europe market for Human-mouse Chimeric Antibody is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.

Global key Human-mouse Chimeric Antibody players cover Roche AG, Johnson & Johnson, Celltrion, Pfizer, Merck KGaA, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.

LPI (LP Information)' newest research report, the “Human-mouse Chimeric Antibody Industry Forecast” looks at past sales and reviews total world Human-mouse Chimeric Antibody sales in 2024, providing a comprehensive analysis by region and market sector of projected Human-mouse Chimeric Antibody sales for 2025 through 2031. With Human-mouse Chimeric Antibody sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Human-mouse Chimeric Antibody industry.

This Insight Report provides a comprehensive analysis of the global Human-mouse Chimeric Antibody landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Human-mouse Chimeric Antibody portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Human-mouse Chimeric Antibody market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Human-mouse Chimeric Antibody and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Human-mouse Chimeric Antibody.

This report presents a comprehensive overview, market shares, and growth opportunities of Human-mouse Chimeric Antibody market by product type, application, key players and key regions and countries.

Segmentation by Type:
Infliximab
Rituximab
Emicizumab
Cetuximab
Esatuximab
Other

Segmentation by Application:
Cancers
Autoimmune Diseases
Transplant Rejection

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Roche AG
Johnson & Johnson
Celltrion
Pfizer
Merck KGaA
Sanofi
Teva
Eli Lilly & Co
Amgen
Merck & Co
Sandoz
Shanghai Henlius Biopharmaceutical
United Therapeutics
Innovent Bio
Mitsubishi Tanabe Pharma
Kyowa Kirin

Please note: The report will take approximately 2 business days to prepare and deliver.

Table of Contents

139 Pages
*This is a tentative TOC and the final deliverable is subject to change.*
1 Scope of the Report
2 Executive Summary
3 Human-mouse Chimeric Antibody Market Size by Player
4 Human-mouse Chimeric Antibody by Region
5 Americas
6 APAC
7 Europe
8 Middle East & Africa
9 Market Drivers, Challenges and Trends
10 Global Human-mouse Chimeric Antibody Market Forecast
11 Key Players Analysis
12 Research Findings and Conclusion
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.